[1]孙素红,周晓玲,李泽鹏,等.柴胡当归散加减联合穴位注射丹参注射液治疗乙肝肝纤维化临床观察[J].陕西中医,2024,(4):477-480,489.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.009]
　SUN Suhong,ZHOU Xiaoling,LI Zepeng,et al.Clinical observation on the treatment of liver fibrosis in hepatitis B with modified Chaihu Danggui powder combined with acupoint injection of Danshen injection[J].,2024,(4):477-480,489.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.009]
点击复制

柴胡当归散加减联合穴位注射丹参注射液治疗乙肝肝纤维化临床观察
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年4期
页码:
477-480,489
栏目:
临床研究
出版日期:
2024-04-05

文章信息/Info

Title:
Clinical observation on the treatment of liver fibrosis in hepatitis B with modified Chaihu Danggui powder combined with acupoint injection of Danshen injection
作者:
孙素红1; 2; 周晓玲3; 李泽鹏3; 覃杏幸2; 孙东琪1; 磨奕玲1; 黄华萍1
(1.广西中医药大学研究生院,广西 南宁 530001; 2.广西科技大学第一附属医院,广西 柳州 545001; 3.柳州市中医医院,广西 柳州 545001)
Author(s):
SUN Suhong; ZHOU Xiaoling; LI Zepeng; QIN Xingxing; SUN Dongqi; MO Yiling; HUANG Huaping
(Graduate School of Guangxi University of Traditional Chinese Medicine,Nanning 530001,China)
关键词:
乙型病毒性肝炎;  肝纤维化;  柴胡当归散;  丹参注射液;  穴位注射;  炎症反应
Keywords:
Hepatitis B;  Liver cirrhosis;  Chaihu Danggui powder;  Danshen injection;  Acupoint injection;  Inflammatory reaction
分类号:
R 575
DOI:
DOI:10.3969/j.issn.1000-7369.2024.04.009
文献标志码:
A
摘要:
目的:观察柴胡当归散加减联合穴位注射丹参注射液治疗乙肝肝纤维化的临床疗效。方法:选取乙肝肝纤维化患者86例,采用随机数字表法分为两组,每组43例,对照组予恩替卡韦治疗,观察组在恩替卡韦的基础上予柴胡当归散加减配合穴位注射丹参注射液治疗。2周为1个疗程,两组均连续治疗12个疗程。对比两组疗效,于治疗前后观察两组中医症候积分、肝纤维化指标[透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C)]、肝功能指标[总胆红素(TBIL)、谷丙转氨酶(ALT)、谷草转氨酶(AST)]及肝脏硬度(LSM)差异,记录并比较两组患者不良反应发生率。结果:治疗后,观察组总有效率为95.35%,较对照组的79.07%更高(P<0.05)。观察组胁肋胀痛、胸闷善太息、神疲乏力、性情急躁、脘腹痞闷、小便不利、大便溏薄症候积分低于对照组(均P<0.05)。观察组HA、LN、PC-Ⅲ、Ⅳ-C、TBIL、ALT、AST水平及LSM低于对照组(均P<0.05)。结论:采用柴胡当归散加减配合穴位注射丹参注射液治疗乙肝肝纤维化患者可提升疗效,显著改善患者肝纤维指标及肝功能,降低肝脏硬度。
Abstract:
Objective:To observe the clinical effect of modified Chaihu Danggui powder combined with acupoint injection of Danshen injection in the treatment of liver fibrosis in hepatitis B.Methods:A total of 86 patients who were diagnosed with liver fibrosis in hepatitis B were selected.They were divided into two groups by the random number table method,with 43 cases in each group.Patients in the control group were treated with enticavir,while those in the observation group were treated with modified Chaihu Danggui powder combined with acupoint injection of Danshen injection on the basis of enticavir treatment.With two weeks as a course of treatment,both groups received 12 courses of treatment.Therapeutic effects in the two groups were compared.Differences in TCM syndrome scores,liver fibrosis indicators [hyaluronic acid(HA),laminin(LN),type Ⅲ procollagen(PC-Ⅲ)and type Ⅳ collagen(Ⅳ-C)],liver function indicators [total bilirubin(TBIL),alanine transaminase(ALT)and aspartate transaminase(AST)] and liver stiffness measurement(LSM)before and after treatment were observed.The incidence rates of adverse reactions were recorded.Results:After treatment,the total effective rate in the observation group(95.35%)was higher than that in the control group(79.07%)(P<0.05).The scores for swelling and pain in the ribs,chest tightness,fatigue and fatigue,irritability,abdominal distension,poor urination and thin sloppy stool in the observation group were lower than those in the control group(all P<0.05).The levels of HA,LN,PC-Ⅲ,Ⅳ-C,TBIL,ALT and AST,and LSM in the observation group were lower than those in the control group(all P<0.05).Conclusion:Chaihu Danggui powder combined with acupoint injection of Danshen injection in the treatment of hepatitis B liver fibrosis patients can improve the curative effect,significantly improve the liver fiber index,liver function,and reduce the liver hardness.

参考文献/References:

[1] ALBERTS C J,CLIFFORD G M,GEORGES D,et al.Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country,region,and global levels:A systematic review[J].Lancet Gastroenterol Hepatol,2022,7(8):724-735.
[2] 蒋淑莲,谭善忠,文剑.柴芍六君汤治疗慢性乙型肝炎肝纤维化疗效及对患者血清Treg/Th17的影响[J].陕西中医,2021,42(9):1229-1232.
[3] 田艳茹.miR-133b与慢性乙型肝炎肝纤维化相关性研究[J].陕西医学杂志,2023,52(4):448-451.
[4] 李健,李连文,王丽华,等.血清白细胞介素-27水平与慢性乙型肝炎患者肝纤维化的关系[J].实用临床医药杂志,2022,26(18):63-66.
[5] 侯艾林,贺汉军,唐剑萍.复方丹参注射液联合替诺福韦酯治疗对乙肝肝硬化失代偿期肝脏硬度及血清Th1/Th2型细胞因子表达的影响[J].中华中医药学刊,2022,40(11):69-72.
[6] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版)[J].中华肝脏病杂志,2019,27(3):182-191.
[7] 中国中西医结合学会消化系统疾病专业委员会.肝纤维化中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(12):895-900.
[8] 国家食品药品监督管理总局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:143-151.
[9] 王文玲,张馨元,叶松,等.丙氨酸氨基转移酶水平对Fibro Touch检测慢性乙型肝炎患者肝脏硬度值的影响研究[J].中国全科医学,2021,24(30):3842-3847.
[10] FRIEDMAN S L,PINZANI M.Hepatic fibrosis 2022:Unmet needs and a blueprint for the future[J].Hepatology,2022,75(2):473-488.
[11] 苟芳,张红军,王洁,等.黄连解毒汤通过抑制TGF-β信号通路减轻2型糖尿病大鼠肝脂肪变性和纤维化研究[J].陕西中医,2022,43(2):170-176.
[12] 李娟,曹平虎,唐先梅,等.双环醇片联合恩替卡韦治疗慢性乙型肝炎疗效及对患者肝功能的保护作用[J].陕西医学杂志,2021,50(10):1271-1274.
[13] 张露,范志芳,刘殿武,等.1990-2016年中国乙型肝炎引起的肝硬化及其他慢性肝病疾病负担变化趋势分析[J].中华流行病学杂志,2020,41(2):173-177.
[14] 毛奕懿,张淑文,安世栋,等.从“肝热脾寒”运用柴胡桂枝干姜汤经验探析[J].天津中医药,2023,40(4):427-430.
[15] 钟培玲,刘林华,贺劲松.针灸治疗非酒精性脂肪性肝病的研究进展[J].广州中医药大学学报,2022,39(3):727-734.
[16] 张馨月,石莉杰,毋亚男,等.口服芩连愈疡汤联合丹参注射液穴位注射治疗非甾体抗炎药相关消化性溃疡脾胃湿热证31例临床观察[J].中医杂志,2022,63(21):2046-2051.
[17] 阮博文,周晓玲,覃凤传,等.柴胡当归散治疗少阳太阴合病证乙肝肝硬化腹水[J].中国临床研究,2021,34(1):102-106.
[18] 有曼,张虹,何广宏,等.柴胡皂苷b2通过调控沉默信息调节因子6介导的糖代谢通路减轻二乙基亚硝胺诱导的小鼠原发性肝癌[J].中国药理学与毒理学杂志,2022,36(10):739-745.
[19] 黄祎,夏莉,雷青松,等.柴胡皂苷D对大鼠免疫性肝纤维化的保护作用及其机制研究[J].陆军军医大学学报,2022,44(14):1410-1420.
[20] 贾岚,王蕾蕾,孟靓,等.白芍总苷对大鼠化学性肝损伤与肝阴虚证结合模型的影响和机制研究[J].中草药,2020,51(7):1885-1892.
[21] 蔡雯雯,葛小东,李娜,等.牡蛎蛋白酶解物对小鼠慢性酒精性肝损伤的保护作用[J].食品科学,2022,43(17):147-155.
[22] 李铮.白术挥发油对小鼠急性肝损伤的作用及其机制[D].长春:吉林大学,2020.
[23] 张宝瑛,李建志,冯丽莉,等.柴胡桂枝干姜汤对大鼠肝损伤保护作用的评价[J].实验技术与管理,2016,33(11):59-62,67.
[24] 符路娣,李兆新,潘卫松,等.甘草酸二铵联合丹参注射液对CCl4诱导小鼠急性肝损伤的保护作用[J].中药新药与临床药理,2020,31(7):810-814.
[25] 钟镇康,周晓玲,张志杰,等.加味济生肾气汤联合穴位注射丹参注射液治疗慢性乙型肝炎肝纤维化患者的临床观察[J].中西医结合肝病杂志,2023,33(3):242-246.
[26] 王祎,庞旭,张保财,等.柴胡皂苷d对肝星状细胞的作用分析[J].北京化工大学学报(自然科学版),2020,47(5):76-82.

相似文献/References:

[1]雷 玲,闵 珺,刘 锋,等.黄芪对肝纤维化大鼠肝损伤保护作用及机制研究*[J].陕西中医,2020,(9):1192.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.004]
　LEI Ling,MIN Jun,LIU Feng,et al.Study on protective effects and mechanism of astragalus on hepatic injury of rats with hepatic fibrosis[J].,2020,(4):1192.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.004]
[2]蒋淑莲,谭善忠,文 剑.柴芍六君汤治疗慢性乙型肝炎肝纤维化疗效及对患者血清Treg/Th17的影响[J].陕西中医,2021,(9):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]
　JIANG Shulian,TAN Shanzhong,WEN Jian.Therapeutic effect of Chaishao Liujun decoction on hepatic fibrosis in chronic hepatitis B and effect on serum Treg/Th17[J].,2021,(4):1229.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.020]
[3]蔡 菁,葛亚强,许丽娟,等.蒿属香豆素对MCD饮食诱导的非酒精性脂肪性肝纤维化小鼠保护性作用的研究[J].陕西中医,2021,(11):1511.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.004]
　CAI Jing,GE Yaqiang,XU Lijuan,et al.Protective effect of scoparone on MCD diet induced liver fibrosis in mice[J].,2021,(4):1511.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.004]
[4]吴必建,章一凡.猪苓汤加味联合多烯磷脂酰胆碱治疗早期肝硬化疗效研究[J].陕西中医,2021,(12):1706.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.013]
[5]苟 芳,张红军,王 洁,等.黄连解毒汤通过抑制TGF-β信号通路减轻2型糖尿病大鼠肝脂肪变性和纤维化研究[J].陕西中医,2022,(2):170.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.007]
　GOU Fang,ZHANG Hongjun,WANG Jie,et al.Huanglian Jiedu decoction alleviates hepatic steatosis and fibrosis in type 2 diabetic rats through activation of TGF - β signaling pathway[J].,2022,(4):170.[doi:DOI:10.3969/j.issn.1000-7369.2022.02.007]
[6]谢 旭,李国焕,贾文燕,等.参芪软肝汤配合抗病毒药物治疗肝硬化临床研究[J].陕西中医,2024,(6):771.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
　XIE Xu,LI Guohuan,JIA Wenyan,et al.Shenqi Ruangan decoction combined with antiviral drugs in the treatment of liver cirrhosis[J].,2024,(4):771.[doi:DOI:10.3969/j.issn.1000-7369.2024.06.010]
[7]魏涛华,杨文明,宋宇琪,等.名中医杨文明治疗Wilson病患者肝纤维化之肝豆扶木汤理法方药体系探析[J].陕西中医,2025,46(4):527.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.020]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(8216150339); 广西壮族自治区柳州市科技计划项目(2023YRZ0102); 广西中医药大学研究生教育创新计划项目(YCBXJ2022025)
更新日期/Last Update: 2024-04-10